Editorial: Resection and survival

John H. Sampson Division of Neurosurgery,
Department of Surgery and Departments of Pathology,
Immunology, and
Radiation Oncology,
Preston Robert Tisch Brain Tumor Center, and

Search for other papers by John H. Sampson in
Current site
Google Scholar
PubMed Close
 M.D., Ph.D., M.H.Sc.
and
Jenny K. Hoang Radiation Oncology,
Department of Radiology, Duke University Medical Center, Durham, North Carolina

Search for other papers by Jenny K. Hoang in
Current site
Google Scholar
PubMed Close
 M.B.B.S.
Page Range:
1169–1171
Volume/Issue:
Volume 116: Issue 6
DOI link:
https://doi.org/10.3171/2011.10.JNS111437
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $525.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $624.00
Click here for subscription options

  • Purchase Now

    USD  $45.00

  • JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

    USD  $525.00

  • JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

    USD  $624.00
USD  $45.00
USD  $525.00
USD  $624.00
Print or Print + Online Sign in
  • Collapse
  • Expand

Contributor Notes

Please include this information when citing this paper: published online March 16, 2012; DOI: 10.3171/2011.10.JNS111437.

Page Count:
3
  • 1

    Brandes AA, , Tosoni A, , Spagnolli F, , Frezza G, , Leonardi M, & Calbucci F, et al.: Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10:361–367, 2008

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Brandsma D, , Stalpers L, , Taal W, , Sminia P, & van den Bent MJ: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461, 2008

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Clarke LP, , Velthuizen RP, , Camacho MA, , Heine JJ, , Vaidyanathan M, & Hall LO, et al.: MRI segmentation: methods and applications. Magn Reson Imaging 13:343–368, 1995

  • 4

    Clarke LP, , Velthuizen RP, , Clark M, , Gaviria J, , Hall L, & Goldgof D, et al.: MRI measurement of brain tumor response: comparison of visual metric and automatic segmentation. Magn Reson Imaging 16:271–279, 1998

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Dempsey MF, , Condon BR, & Hadley DM: Measurement of tumor “size” in recurrent malignant glioma: 1D, 2D, or 3D?. AJNR Am J Neuroradiol 26:770–776, 2005

  • 6

    Friedman HS, , Prados MD, , Wen PY, , Mikkelsen T, , Schiff D, & Abrey LE, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740, 2009

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245–3251, 2006

  • 8

    Joe BN, , Fukui MB, , Meltzer CC, , Huang QS, , Day RS, & Greer PJ, et al.: Brain tumor volume measurement: comparison of manual and semiautomated methods. Radiology 212:811–816, 1999

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Kanaly CW, , Ding D, , Mehta AI, , Waller AF, , Crocker I, & Desjardins A, et al.: A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One 6:e16031, 2011

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Macdonald DR, , Cascino TL, , Schold SC Jr, & Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280, 1990

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Moonis G, , Liu J, , Udupa JK, & Hackney DB: Estimation of tumor volume with fuzzy-connectedness segmentation of MR images. AJNR Am J Neuroradiol 23:356–363, 2002

  • 12

    Pham DL, , Xu C, & Prince JL: Current methods in medical image segmentation. Annu Rev Biomed Eng 2:315–337, 2000

  • 13

    Polley MY, , Lamborn KR, , Chang SM, , Butowski N, , Clarke JL, & Prados M: Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol 12:274–282, 2010

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Reardon DA, , Galanis E, , DeGroot JF, , Cloughesy TF, , Wefel JS, & Lamborn KR, et al.: Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 13:353–361, 2011

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Sankar T, , Moore NZ, , Johnson J, , Ashby LS, , Scheck AC, & Shapiro WR, et al.: Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors. Clinical article. J Neurosurg [epub ahead of print March 16, 2012. DOI: 10.3171/2012.2.JNS102032]

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Shah GD, , Kesari S, , Xu R, , Batchelor TT, , O'Neill AM, & Hochberg FH, et al.: Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol 8:38–46, 2006

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17

    Therasse P, , Arbuck SG, , Eisenhauer EA, , Wanders J, , Kaplan RS, & Rubinstein L, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216, 2000

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Vaidyanathan M, , Clarke LP, , Hall LO, , Heidtman C, , Velthuizen R, & Gosche K, et al.: Monitoring brain tumor response to therapy using MRI segmentation. Magn Reson Imaging 15:323–334, 1997

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    van den Bent MJ, , Vogelbaum MA, , Wen PY, , Macdonald DR, & Chang SM: End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 27:2905–2908, 2009

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Wen PY, , Macdonald DR, , Reardon DA, , Cloughesy TF, , Sorensen AG, & Galanis E, et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group. J Clin Oncol 28:1963–1972, 2010

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Wu W, , Lamborn KR, , Buckner JC, , Novotny PJ, , Chang SM, & O'Fallon JR, et al.: Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol 12:164–172, 2010

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 1

    Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245–3251, 2006

  • 2

    Macdonald DR, , Cascino TL, , Schold SC Jr, & Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280, 1990

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Sanai N, , Polley MY, , McDermott MW, , Parsa AT, & Berger MS: An extent of resection threshold for newly diagnosed glioblastomas. Clinical article. J Neurosurg 115:3–8, 2011

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Sled JG, , Zijdenbos AP, & Evans AC: A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 17:87–97, 1998

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 635 45 4
Full Text Views 82 5 4
PDF Downloads 72 1 0
EPUB Downloads 0 0 0